On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...